Sanofi's Rilzabrutinib Could Revolutionize Cancer Treatments
Why you should consider buying Sanofi
Sanofi's rilzabrutinib performed well in its phase 3 clinical trial, meaning the company can now apply for approval. The drug is a type of BTK inhibitor that combats disorders found in B lymphocytes, also known as B cells. BTK inhibitors have shown effectiveness as a treatment for such diseases as non-Hodgkin lymphomas.
The excitement over its clinical trial success
Rilzabrutinib works at a smaller dosage and has fewer unwanted side effects. Those traits immediately make the drug promising in the marketplace.
- Rilzabrutinib's ability to work effectively in low dosages
- Developers confident that the drug could be used against other diseases
Where Sanofi is now
Sanofi began 2024 with a 7% increase in Q1 sales, beating analysts' expectations. The company had a share price of $49.23 at the close of April 30, which put it halfway between its 52-week high of $55.93 and its 52-week low of $42.63.
Sanofi's yearly gross profit margin
Sanofi's yearly gross profit margin of 68.5% and its 17.8% free cash flow margin are higher than the sector's median.
- Declining sales of insulin drug Lantus affected cash flow margin
- Expiry impact on Q1 gross margin due to multiple sclerosis drug Aubagio
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.